安进开发了 MariTide，这是一种每月一次的减肥注射剂，有可能在治疗后维持减肥效果。 Amgen develops MariTide, a monthly weight loss injection potentially maintaining weight loss after treatment.

安进公司正在开发一种每月一次的减肥注射液 MariTide，它与 Wegovy 和 Zepbound 等竞争对手的药物不同，即使在停止治疗后也可以帮助患者保持体重减轻。 Amgen is developing a monthly weight loss injection, MariTide, that differs from rival drugs like Wegovy and Zepbound, and may help patients maintain weight loss even after stopping treatment. 需要更多数据来评估该疗法在肥胖市场的竞争力。 More data is needed to assess the treatment's competitiveness in the obesity market. 安进的目标是在减肥药物开发商这个拥挤的领域中脱颖而出。 Amgen aims to distinguish itself in the crowded field of weight loss drug developers.